HSA | FSA CARDS ARE NOW ACCEPTED

This article is part of the PlexusDx Education Hub — your resource for evidence-based guidance on GLP-1 therapies, weight management protocols, and the genetic variables that shape every metabolic decision. Browse all Peptides & GLP-1 education

"glp agonist" is a pathway-level question about GLP-1 receptor agonists as a drug class. This article covers what GLP-1 is as a hormone, how receptor agonists work mechanically, which medications belong to the class, the FDA-approved indications, the shared safety profile, and the genetic variables that sit upstream of every GLP-1 decision.

What GLP-1 is

Glucagon-like peptide-1 (GLP-1) is an incretin hormone produced by enteroendocrine L-cells in the small intestine in response to food. It stimulates glucose-dependent insulin secretion from pancreatic beta cells, suppresses glucagon release from alpha cells, slows gastric emptying, and signals satiety in the hypothalamus. Native GLP-1 has a very short half-life (minutes) because the enzyme DPP-4 degrades it rapidly in circulation.

How GLP-1 receptor agonists work

GLP-1 receptor agonists are peptides (or small molecules in emerging cases) that engage the GLP-1 receptor and resist DPP-4 degradation — extending half-life from minutes to hours or days. They deliver the physiological effects of native GLP-1 at a pharmacological level: glucose-dependent insulin secretion, glucagon suppression, delayed gastric emptying, and reduced appetite via central satiety signaling. GIP/GLP-1 dual agonists (tirzepatide) additionally engage the GIP receptor, adding a second incretin mechanism.

Which medications are GLP-1 receptor agonists

FDA-approved GLP-1 receptor agonists as of April 2026 include: exenatide (Byetta, Bydureon), liraglutide (Victoza, Saxenda), dulaglutide (Trulicity), lixisenatide (historically; discontinued in the U.S.), and semaglutide (Ozempic, Wegovy, Rybelsus). The GIP/GLP-1 dual agonist is tirzepatide (Mounjaro, Zepbound). The investigational triple agonist retatrutide (GLP-1 / GIP / glucagon) has Phase 3 data but is not FDA-approved. Emerging oral non-peptide GLP-1 receptor agonists (e.g., orforglipron) are in late-stage development.

FDA-approved indications across the class

Indications vary by compound and product: type 2 diabetes (most products), chronic weight management (Wegovy, Saxenda, Zepbound), cardiovascular risk reduction in type 2 diabetes (Ozempic, Trulicity, Victoza, Rybelsus), and obstructive sleep apnea in adults with obesity (Zepbound, December 2024). Pediatric indications exist for certain products. FDA labeling governs what is prescribed for which indication — discuss specific indications with a healthcare provider.

Shared safety profile

All FDA-approved GLP-1 receptor agonists and GIP/GLP-1 dual agonists carry the class boxed warning for thyroid C-cell tumor risk observed in rodent studies. Contraindications include personal or family history of medullary thyroid carcinoma and Multiple Endocrine Neoplasia syndrome type 2. The most common side effects are gastrointestinal (nausea, vomiting, diarrhea, constipation) and typically most pronounced during dose escalation. Serious adverse events reported in clinical use include pancreatitis, gallbladder events, and acute kidney injury in the context of dehydration.

The genetic variable

Variants in FTO, GLP1R, MC4R, and TCF7L2 shape baseline GLP-1, appetite-regulation, and energy-balance biology. These variants are pathway-level; they do not predict response to any one compound in the class, but they do describe the biological terrain every GLP-1 compound operates on. See the PlexusDx primer What is GLP-1? for the pathway explanation.

PlexusDx offers semaglutide and tirzepatide through its Weight Management Protocols — available as Semaglutide Injection, Semaglutide Oral, Tirzepatide Injection, and Tirzepatide Oral. What sets the PlexusDx approach apart is the upstream genetic context. Before starting any GLP-1 pathway protocol, the Precision Peptide Genetic Test analyzes 14 pathways, 49 peptides, and 150+ genetic insights — including variants in FTO, GLP1R, MC4R, TCF7L2 that shape your baseline GLP-1, appetite-regulation, and energy-balance biology. Knowing that genetic profile alongside the protocol itself is the test before you invest approach — turning guesswork into an informed conversation with your healthcare provider.

Related reading on PlexusDx: GLP-1 Hormone, What Is GLP-1?, GLP-1 Receptor Agonist.

Disclaimer: This article is educational. PlexusDx offers semaglutide and tirzepatide through its Weight Management Protocols — this article covers the mechanism, evidence, and genetic context that informs any decision to use them. PlexusDx does not sell, prescribe, or recommend any other therapeutic peptide in the GLP-1 category beyond semaglutide and tirzepatide (including dulaglutide, liraglutide, retatrutide, cagrilintide, and related compounds). The Precision Peptide Genetic Test analyzes how your genes influence peptide-related biological pathways — it does not predict response to any specific medication. Consult a qualified healthcare provider before beginning any peptide protocol.

Start with the biology. Take the Precision Peptide Genetic Test, or explore the Weight Management Protocols.

Frequently Asked Questions

What is a GLP-1 receptor agonist?

A GLP-1 receptor agonist is a peptide (or emerging small molecule) that engages the GLP-1 receptor and resists rapid degradation. It stimulates glucose-dependent insulin secretion, slows gastric emptying, and signals satiety. FDA-approved agonists include semaglutide, tirzepatide (GIP/GLP-1 dual), liraglutide, and dulaglutide.

How are GLP-1 receptor agonists different from GIP/GLP-1 dual agonists?

GLP-1 receptor agonists engage only the GLP-1 receptor. GIP/GLP-1 dual agonists (tirzepatide) additionally engage the GIP receptor — adding a second incretin mechanism. Clinical trial data (SURPASS, SURMOUNT) suggests that the dual-receptor mechanism may produce larger mean effects on weight and glycemic control in some trial populations.

Does genetic testing predict response to GLP-1 receptor agonists?

No. The Precision Peptide Genetic Test does not predict response to any specific compound in the class. It analyzes pathway-level variants in FTO, GLP1R, MC4R, and TCF7L2 that shape baseline GLP-1 and energy-balance biology — the upstream context that applies across every GLP-1 receptor agonist and GIP/GLP-1 dual agonist.

Who should not use a GLP-1 receptor agonist?

Patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 are contraindicated per all FDA labels in the class. Patients with severe gastrointestinal disease, a history of pancreatitis, or specific other conditions require careful clinical review. Discuss full history with a provider.

This article is part of the PlexusDx Education Hub. Browse all Peptides & GLP-1 education